Navigation Links
Expression Genetics' EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover
Date:9/5/2008

HUNTSVILLE, Ala., Sept. 5 /PRNewswire/ -- Expression Genetics, Inc. (EGEN) announced today that the company's novel TheraPlas(R) cancer drug has been selected as one of the Top 10 most promising oncology products in development available for strategic partnering. The selection was made by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology, and medical device industries.

"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committee considered the most attractive oncology opportunities the industry has to offer," said Roger Longman, Managing Director of Windhover Information. "Winners have met rigorous criteria including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications, and corporate stability."

"We are honored that Windhover has recognized the potential of EGEN-001 to address serious unmet needs in cancer treatment," said Dr. Danny H. Lewis, president and chief executive officer of Expression Genetics. "With its unique profile, proprietary delivery system technology, and results to date, EGEN-001 has demonstrated ability to address a number of tumor types and represents a potentially important new approach to treat a wide range of cancers. We look forward to continuing our efforts to advance this promising product compound through clinical development."

The selection committee was led by Marc Wortman, Ph.D., contributing writer to Windhover's In Vivo and Start Up, and a team from Campbell Alliance, a leading business development strategy consulting firm. Drawing on the analytic resources of these organizations, the group evaluated hundreds of compounds currently in development for the treatment of cancer prior to selecting EGEN-001 to be among the top ten most attractive oncology products available for strategic partnering.

As a selected company, Expression Genetics has been invited to present data on EGEN-001 TheraPlas(R) IL-12 oncology product at Windhover's Therapeutic Area Partnerships conference on November 3-5, 2008, in Philadelphia, PA.

About EGEN-001 TheraPlas(TM) Oncology Product

EGEN-001 is under development for the treatment of advanced recurrent ovarian cancer, as well as other local or disseminated solid tumors. The product is based on proprietary TheraPlas(R) delivery technology. It is composed of an interleukin-12 (IL-12) gene expression plasmid and a biocompatible delivery polymer. IL-12 is a potent cytokine which works by multiple mechanisms of action to enhance the body's immune system against cancer and inhibit tumor blood supply. EGEN-001 has completed a Phase I monotherapy trial with promising results and is currently in the final stage of a Phase IA trial designed to evaluate safety and preliminary efficacy of the drug when administered in combination with conventional chemotherapy treatment. EGEN-001 received Orphan Drug Status from the FDA in 2005 and a $1 million FDA Orphan Grant in 2007.

About Windhover

Windhover Information Inc., an Elsevier company, has led the field in providing analysis of the healthcare industry to decision-makers at all levels since the founding of its flagship publication, IN VIVO, The Business & Medicine Report, in 1983. Windhover provides its information and analysis in many formats, including print, electronic databases, international conferences and webinars. For more on the company's products and services, please see http://www.windhover.com

About Expression Genetics, Inc.

Expression Genetics, Inc. (EGEN), is a privately held biopharmaceutical company specializing in nucleic acid (DNA and RNAi) delivery and therapeutics aimed at specific disease targets. The Company, with laboratories and headquarters in Huntsville, Alabama, is focused on developing therapeutics for the treatment of human diseases including cancer and cardiovascular disease. The Company has a significant intellectual property position in biocompatible polymers, their novel compositions with nucleic acids, and their therapeutic applications. EGEN has research pipeline products aimed at treatment of various cancers and cardiovascular disease involving siRNA, shRNA, tumor antigens, and angiogenic genes. EGEN has collaborations with outside investigators, biotech organizations and universities on various projects in these areas.

Safe Harbor for Forward Looking Statements

Certain statements contained in this press release may be deemed to be forward looking statements under federal securities laws and Expression Genetics intends that such forward looking statements be subject to the safe harbor created thereby. Expression Genetics does not undertake an obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise. Actual events or results may differ from our expectations as a result of a number of factors, including but not limited to uncertainties in clinical trials and product development programs, ability and success level of the Company in securing adequate capital for operations, market place acceptance of any resulting product and other factors common to biotechnology research and development. There can be no guarantee that any product in our pipeline will be successfully developed.

Further information about Expression Genetics can be found at: http://www.egencorp.com


'/>"/>
SOURCE Expression Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award
2. Xceed Ziplex(R) System for Automated Gene-Expression Analysis Wins 2008 R&D 100 Award
3. Xceed Molecular to Launch New Inflammation Xpress Chip(TM)for the Ziplex(R) Automated Gene-Expression Analysis System at Clinical Lab Expo 2008, Booth 2155
4. Xceed Molecular Features Ziplex(R) Automated Gene-Expression System at the Biomarker World Congress, Booth 16
5. ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics
6. Caliper Life Sciences Introduces High Throughput RNA Assay to Improve Workflow in Gene Expression Studies
7. Interleukin Genetics and Alticor Agree on Expansion of Distribution Channels for Genetic Tests
8. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Healthcare Conference 2008
9. Interleukin Genetics Licenses its PST(R) Genetic Test to OralDNA Labs
10. deCODE genetics Announces Second Quarter 2008 Financial Results
11. Interleukin Genetics Announces Conference Call and Webcast to Discuss Second Quarter 2008 Business Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Florida , March 22, 2017 ... ... various cancer conditions are being pressured as of late due ... for cancer pain management has a dramatic impact on patient,s ... research and development activities for identifying new forms of opioid ...
(Date:3/22/2017)... 2017   Boston Biomedical , an industry leader ... target cancer stemness pathways, today announced its Board of ... Chief Executive Officer, effective April 24, 2017. ... , M.D., FACP, who has led Boston Biomedical since ... leadership, Boston Biomedical has grown from a "garage startup" ...
(Date:3/22/2017)... ... ... executive recruitment firm, Slone Partners, is proud to have been named a Top 50 ... Scanlon Media is one of the most respected life science publications in the United ... , “It is a great honor for Slone Partners to be part of this ...
(Date:3/22/2017)... ... March 21, 2017 , ... Proper glycosylation is critical ... desired increase and/or decrease in antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity, there is ... antibodies. , To meet this demand, the team at SCIEX has developed ...
Breaking Biology Technology:
(Date:3/2/2017)... YORK , March 2, 2017 Summary ... better understand Perrigo and its partnering interests and activities since ... ... Partnering Deals and Alliance since 2010 report provides an in-depth ... leading life sciences companies. On demand company reports ...
(Date:3/2/2017)... 2017 Australian stem cell and regenerative medicine ... signed an agreement with the Monash Lung Biology Network, ... Institute and Department of Pharmacology at Monash University, ... study to support the use of Cymerus™ mesenchymal stem ... Asthma is a chronic, long term lung condition ...
(Date:2/28/2017)... , February 28, 2017 News solutions for ... ... from 14 to 16 March, Materna will present ... show how seamless travel is a real benefit for passengers. ... biometrics to their passenger touch point solutions to take passengers through ...
Breaking Biology News(10 mins):